1. In this randomized controlled trial, aficamten significantly improved peak oxygen uptake in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) compared with placebo. 2. The results for all 10 secondary endpoints were significantly improved with aficamten. Evidence Rating Level: 1 (Excellent) Study Rundown: HCM is one of the most common genetic heart diseases and is
Early Increase in Serum Transthyretin Level Is an Independent Predictor of Improved Survival in ATTR Cardiomyopathy: Insights From Acoramidis Phase 3 Study ATTRibute-CM .
Heart Failure Patients Who Do Yoga Have Stronger Hearts and Can be More Active dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.